Nevertheless, the absence of significant changes in swollen joint count (SJC), STAT3, and TGF-β1 within the L-carnitine group may indicate that certain pathological aspects of RA—particularly those involving deeper synovial or structural alterations—might necessitate extended treatment durations or higher dosages to elicit a therapeutic response. The gene discussed is TGFB1; the disease is rheumatoid arthritis.